Valneva SE (VIE:VLA)

Austria flag Austria · Delayed Price · Currency is EUR
3.096
-0.036 (-1.15%)
Last updated: Apr 24, 2025
-14.57%
Market Cap 526.51M
Revenue (ttm) 169.58M
Net Income (ttm) -12.25M
Shares Out n/a
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 9,444
Open 3.124
Previous Close 3.132
Day's Range 3.078 - 3.124
52-Week Range 1.747 - 4.240
Beta 1.29
RSI 50.53
Earnings Date May 7, 2025

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by c... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 713
Stock Exchange Vienna Stock Exchange
Ticker Symbol VLA
Full Company Profile

Financial Performance

In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.

Financial Statements

News

There is no news available yet.